Quantifying such a mediating effect could clarify how lipid-related atherogenic risk intersects with obesity-driven metabolic dysfunction to influence cardiovascular diseases, insights that may inform targeted interventions, such as addressing insulin resistance to mitigate both lipid abnormalities and obesity-related risk. This evidence concerns the gene INS and obesity disorder.